Elicio Therapeutics Director Resigns
Ticker: ELTX · Form: 8-K · Filed: Aug 30, 2024 · CIK: 1601485
| Field | Detail |
|---|---|
| Company | Elicio Therapeutics, Inc. (ELTX) |
| Form Type | 8-K |
| Filed Date | Aug 30, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: director-resignation, governance, officer-compensation
TL;DR
Rothberg out at Elicio. Board shakeup.
AI Summary
Elicio Therapeutics, Inc. announced on August 27, 2024, a change in its board of directors. Specifically, Dr. Jonathan M. Rothberg has resigned from his position as a Class II Director. The company also reported on compensatory arrangements for its officers.
Why It Matters
A director's resignation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Director resignations can sometimes precede or coincide with other significant company events, warranting closer monitoring.
Key Players & Entities
- Elicio Therapeutics, Inc. (company) — Registrant
- Dr. Jonathan M. Rothberg (person) — Resigning Director
- August 27, 2024 (date) — Date of earliest event reported
FAQ
Who is Dr. Jonathan M. Rothberg and what was his role at Elicio Therapeutics?
Dr. Jonathan M. Rothberg was a Class II Director at Elicio Therapeutics, Inc.
When did Dr. Jonathan M. Rothberg's resignation become effective?
The filing reports the earliest event as August 27, 2024, indicating the resignation likely occurred on or around this date.
What other information is provided in this 8-K filing besides the director's resignation?
The filing also covers the election of directors and the appointment of certain officers, as well as compensatory arrangements of certain officers.
What is Elicio Therapeutics, Inc.'s primary business?
Elicio Therapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
What was Elicio Therapeutics, Inc. formerly known as?
Elicio Therapeutics, Inc. was formerly known as Angion Biomedica Corp.
Filing Stats: 458 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-08-30 08:30:16
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share ELTX The Nasdaq
Filing Documents
- ef20035237_8k.htm (8-K) — 24KB
- 0001140361-24-039592.txt ( ) — 159KB
- eltx-20240827.xsd (EX-101.SCH) — 4KB
- eltx-20240827_lab.xml (EX-101.LAB) — 22KB
- eltx-20240827_pre.xml (EX-101.PRE) — 16KB
- ef20035237_8k_htm.xml (XML) — 4KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 27, 2024 Elicio Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-39990 11-3430072 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 451 D Street, 5th Floor Boston , Massachusetts 02210 (Address of principal executive offices and Zip Code) ( 857 ) 209-0050 (Registrant's Telephone Number, Including Area Code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value per share ELTX The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 27, 2024, Brian Piekos, the Chief Financial Officer and Treasurer of Elicio Therapeutics, Inc. (the "Company"), informed the Company of his intent to resign from his positions, effective September 6, 2024, to pursue another opportunity. Mr. Piekos' resignation is not the result of any disagreement with the Company on any matter related to the Company's financial reporting or accounting policies, procedures, estimates or judgments. The Company thanks Mr. Piekos for his service and wishes him well. The Company has initiated a search for a new Chief Financial Officer. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Elicio Therapeutics, Inc. Date: August 30, 2024 By: /s/ Robert Connelly Name: Robert Connelly Title: President and Chief Executive Officer (Principal Executive Officer)